Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

July 18th 2022

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.

Overview of Treatment Options in HER2+ Metastatic Breast Cancer

July 18th 2022

Shared insight on the treatment armamentarium for patients diagnosed with HER2+ metastatic breast cancer.

Perspectives on the Current Treatment Landscape of TNBC

July 18th 2022

Expert oncologists share insight on the prognosis of triple-negative breast cancer (TNBC) and broadly review current treatment options for patients.

Frontline Combination Strategies in HR+/HER2- BC

July 18th 2022

A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.

Escalation or Deescalation of Therapy in Early-Stage HER2+ Breast Cancer

July 18th 2022

Before closing out their discussion on early-stage HER2+ breast cancer, expert oncologists define the value of escalating or deescalating therapy.

Optimized Therapy Requires More Than Binary Understanding of HER2 Positivity in Metastatic Breast Cancer

July 16th 2022

Neratinib-based combinations, antibody-drug conjugates, and bispecific antibodies represent novel and effective treatment options for patients with pretreated HER2-mutant and HER2-low metastatic breast cancer, but the successful integration of these regimens into care will require further investigation into current definitions of HER2 positivity.

ADCs With Non-Cytotoxic Payloads May Represent the Future of HER2+ Breast Cancer Treatment

July 16th 2022

The emergence of novel agents like trastuzumab deruxtecan and tucatinib in the HER2-positive breast cancer treatment paradigm have served to markedly improve outcomes for those with this disease, according to Mark Pegram, MD, who added that the future looks bright.

Intrinsic Tumor Subtyping Is Key To Breast Cancer Treatment

July 15th 2022

Charles M. Perou, PhD, discusses the role of intrinsic tumor subtyping in treatment decisions and outcomes for patients with breast cancer.

Treatment Strategies Evolve With Increased Disease Specification in HER2+ Breast Cancer

July 15th 2022

Adrienne G. Waks, MD, highlights clinical trials that are studying emerging treatment escalation and de-escalation strategies in early stage HER2-positive breast cancer, elaborates on the future of immunotherapy in this setting, and explains the significance of establishing new biomarkers.

Ovarian Function Suppression Drives Chemotherapy Benefits in Premenopausal HR+/HER2- Breast Cancer

July 15th 2022

Premenopausal patients with early hormone receptor–positive, HER2-negative breast cancer can benefit from chemotherapy, although it is still debatable whether that benefit stems from the chemotherapy itself or the ovarian function suppression that happens as a result of chemotherapy.

Patient Selection May be Key for Leveraging Elacestrant in ER+/HER2- Breast Cancer

July 13th 2022

Francois-Clement Bidard, MD, PhD, highlights the benefits of elacestrant in chemotherapy-naïve patients and in those with ESR1 mutations, explains the results of a subgroup analysis done of the EMERALD trial in patients without prior chemotherapy, and voices his hopes for the future regarding other oral selective estrogen receptor degraders in development.

Mechanisms of Resistance to CDK4/6- and ER-Targeted Therapy in Metastatic BC

July 13th 2022

Key opinion leaders share insight on various mechanisms of resistance to frontline therapy in patients with HR+/HER2- metastatic breast cancer.

HR+/HER2- Metastatic Breast Cancer: Real-World Data on CDK4/6 Inhibitors

July 13th 2022

A brief review of molecular testing’s role in HR+/HER2- metastatic breast cancer and how certain driver mutations can impact care.

Dr Han on the Significance of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

July 13th 2022

Heather Han, MD, discusses breakthrough data from the phase 3 DESTINY-Breast04 trial.

Dr. Jain on Potential Biomarkers in HR-Positive, HER2-Negative Breast Cancer

July 13th 2022

Amit Jain, MD, discusses the potential role of emerging biomarkers in selecting treatment with CDK7 inhibitors in patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Dr. Bidard on the Importance of Elacestrant in ER+/HER2- Breast Cancer

July 12th 2022

Francois-Clement Bidard, MD, PhD, discusses the importance of elacestrant in estrogen receptor–positive, HER2-negative, advanced or metastatic breast cancer.

FDA Removes Clinical Hold on FLAMINGO-01 Trial in High-Risk HER2/Neu-Positive Breast Cancer

July 12th 2022

The FDA has removed the clinical hold on the phase 3 FLAMINGO-01 trial allowing the study to continue elevating the activity and safety of the HER2/neu-peptide GLSI-100 in patients with HER2/neu-positive breast cancer who are at high risk for disease recurrence or have residual disease following completion of neoadjuvant and adjuvant trastuzumab-based therapy, according to an announcement from the drug developer.

FDA Accepts BLA for Trastuzumab Duocarmazine for Advanced HER2+ Breast Cancer

July 12th 2022

The FDA has accepted for review a biologics license application for vic-trastuzumab duocarmazine for the treatment of patients with HER2-positive unresectable locally advanced or metastatic breast cancer.

Stearns Elaborates on the Evolution of ADCs in HER2+ and HER2-Low Breast Cancer

July 12th 2022

Vered Stearns, MD, FASCO, discusses how DESTINY-Breast04 has shifted the treatment paradigm for patients with HER2-low breast cancer, the exploration of treatment combinations being optimized in breast cancer, and the expansion of the treatment paradigm in triple-negative breast cancer.

Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer

July 11th 2022

Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v